Polatuzumab Vedotin

Polatuzumab vedotin is an antibody–drug conjugate used to treat certain adults with diffuse large B-cell lymphoma (DLBCL), an aggressive type of non-Hodgkin lymphoma arising from B lymphocytes. It combines a monoclonal antibody that recognises CD79b, a protein expressed on many B cells, with monomethyl auristatin E (MMAE), a cytotoxic agent that disrupts microtubules and interferes with cell division. After binding to CD79b, the conjugate is taken into the target cell, where MMAE is released and promotes cell death. This targeted delivery approach helps direct the cytotoxic component toward B cells, although normal B cells and other tissues may also be affected. Polatuzumab vedotin is administered by intravenous infusion under the supervision of a healthcare professional experienced in cancer treatment. It is not generally used alone for the approved DLBCL indications; instead, it is combined with other anticancer medicines according to the treatment setting. Its clinical role includes selected patients receiving initial treatment and adults whose DLBCL has returned or failed to respond to previous therapies. Treatment selection depends on the lymphoma subtype, previous treatment, overall health, laboratory results, and applicable local prescribing guidance. Close monitoring is important because treatment can cause nerve damage, reduced blood-cell counts, infections, and other potentially serious adverse effects.

Polatuzumab vedotin was developed as a CD79b-directed antibody–drug conjugate for B-cell malignancies. The US Food and Drug Administration (FDA) granted its initial approval on 10 June 2019 for use with bendamustine and rituximab in adults with relapsed or refractory DLBCL after at least two prior therapies. The European Medicines Agency (EMA) issued a conditional marketing authorisation on 16 January 2020; this became a full authorisation on 24 May 2022. In April 2023, the FDA expanded its use to include polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for certain adults with previously untreated DLBCL or high-grade B-cell lymphoma. This first-line approval was supported by the phase III POLARIX trial, which compared polatuzumab vedotin plus R-CHP with the established R-CHOP regimen. The trial demonstrated improved progression-free survival with the polatuzumab-containing regimen. Regulatory indications and eligibility criteria vary by jurisdiction, so the current local product information should be checked before treatment.

Polatuzumab vedotin is used in combination with other anticancer medicines for selected adults with DLBCL. In the United States, it is indicated with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for previously untreated DLBCL, not otherwise specified, or high-grade B-cell lymphoma in patients with an International Prognostic Index score of at least 2. It is also indicated with bendamustine and a rituximab product for adults with relapsed or refractory DLBCL, not otherwise specified, after at least two prior therapies. Eligibility and wording of approved indications may differ between countries. Treatment choice depends on disease characteristics, prior therapies, fitness for combination chemotherapy, and the applicable product label. Polatuzumab vedotin is not a general treatment for every lymphoma subtype, and use outside approved indications requires specialist assessment.

Polatuzumab vedotin is given by intravenous infusion, with the dose calculated according to body weight. The usual recommended dose in the US prescribing information is 1.8 mg/kg every 21 days for six cycles, in combination with the appropriate regimen. In previously untreated disease, it is combined with R-CHP; the regimen generally includes two additional cycles of rituximab after the six combination cycles. For relapsed or refractory disease, it is combined with bendamustine and rituximab for the prescribed treatment course. The first infusion is generally administered over 90 minutes; later infusions may be shorter if the initial infusion is tolerated. Premedication with an antihistamine and antipyretic is recommended. Blood counts, liver function, neuropathy, infection risk, and other adverse effects guide treatment decisions. Dose delays, reductions, or discontinuation may be necessary for toxicity. Administration and preparation must follow the current local prescribing information and institutional cytotoxic-drug procedures.

Common side effects include peripheral neuropathy, which may cause numbness, tingling, burning, pain, or weakness in the hands and feet; fatigue; nausea; diarrhoea; constipation; hair loss; and inflammation or soreness of the mouth. Reduced blood-cell counts, including neutropenia, anaemia, and thrombocytopenia, may also occur. In patients receiving polatuzumab vedotin with bendamustine and rituximab, fever, reduced appetite, and pneumonia have also been reported. The frequency and severity of adverse effects vary according to the treatment combination, the patient's health, and previous therapy. Some effects improve with supportive care, while others require dose adjustment or treatment interruption. Patients should report new or worsening numbness, difficulty walking, persistent gastrointestinal symptoms, unusual bruising, fever, or signs of infection promptly to their oncology team.

Important risks include severe or worsening peripheral neuropathy, significant myelosuppression, serious or opportunistic infections, infusion-related reactions, progressive multifocal leukoencephalopathy (PML), tumour lysis syndrome, liver injury, and harm to an unborn baby. Infusion reactions may include chills, fever, rash, or breathing difficulty and require prompt assessment, interruption, or discontinuation of the infusion depending on severity. Tumour lysis syndrome is a particular concern in patients with high tumour burden or rapidly proliferating disease. New neurological, cognitive, or behavioural changes require urgent evaluation for possible PML. Treatment may need to be withheld or the dose reduced for neuropathy, cytopenias, liver abnormalities, or other significant toxicities. If PML is confirmed, the US prescribing information directs permanent discontinuation. Pregnancy must be avoided during treatment according to the relevant contraception guidance. Patients should receive clear instructions on when to seek urgent medical care.

Before treatment, clinicians should assess the patient's medical history, baseline peripheral nerve function, complete blood count, liver function, infection status, and overall fitness for the planned combination regimen. Existing neuropathy may worsen during treatment. Patients with active or recent serious infections, impaired liver function, or significant bone-marrow suppression need careful assessment and monitoring. Strong CYP3A inhibitors or inducers may alter exposure to the unconjugated MMAE component and should be reviewed when assessing concomitant medicines. Live vaccines and vaccination timing should be considered in the context of immunosuppression and the accompanying chemotherapy regimen; vaccination advice should be individualised. Polatuzumab vedotin can cause fetal harm, so pregnancy testing and effective contraception should be addressed for patients with reproductive potential, in accordance with local prescribing guidance. Breastfeeding should be avoided during treatment as specified in the product information. There are no universally interchangeable dosing rules across all patient groups; clinicians should consult the current local label for hepatic impairment, drug interactions, and dose modifications.

Confirm the lymphoma diagnosis, treatment line, relevant eligibility criteria, and intended combination regimen before dispensing or administering polatuzumab vedotin. Document baseline neuropathy symptoms and reassess them before each cycle, as early recognition may prevent worsening nerve injury. Check complete blood counts and liver tests according to the treatment protocol, and assess for fever or other evidence of infection throughout therapy. Follow current guidance for growth-factor support and antimicrobial prophylaxis where indicated, particularly when using bendamustine-containing regimens. Provide recommended antihistamine and antipyretic premedication, monitor the patient during infusion, and ensure appropriate venous access to reduce the risk of extravasation. Pharmacists should verify the weight-based dose, preparation, storage, handling, and disposal requirements for this cytotoxic antibody–drug conjugate. Counsel patients to report tingling, weakness, fever, unusual bleeding, jaundice, infusion reactions, or new neurological symptoms promptly. Coordination among haematology, oncology nursing, pharmacy, and supportive-care teams is important for safe delivery.